David O’Malley, MD, Discusses Findings From the OReO Trial in Ovarian Cancer at 2021 ESMO

Video

CancerNetwork® sat down with David O’Malley, MD, at the 2021 European Society for Medical Oncology to talk about the OReO trial and how these findings impact what’s already known about PARP inhibitors for the treatment of ovarian cancer.

At the 2021 European Society for Medical Oncology Congress, CancerNetwork® spoke with David O’Malley, MD, of The Ohio State University College of Medicine, who said he was excited to see the results of the OreO trial (NCT03106987), which investigated olaparib (Lynparza) maintenance retreatment in ovarian cancer.

Transcript:

The OReO trial, which was presented [at ESMO and] showed the benefit of PARP inhibitors and platinum-sensitive recurrence in the maintenance setting, is interesting. Now, these improvements were modest. However, it did show that one of the best predictors of PARP response is the responsiveness to platinum [therapy]. We need a lot more information from this trial. There are a lot of questions we have [and] very small numbers of responses that we [are using to derive] the overall hazard ratio. For example, what wasn’t presented was the number of patients who had discontinued prior PARP exposure because of toxicity, progression, or [therapy completion]. Some patients had 2 years of treatment with SOLO-1 [NCT01844986] or 3 years with the PRIMA trial [NCT02655016]. Clearly, the patient that does not progress on PARP versus the patient that progresses seems to be a much different patient population. We really need to look at those patients individually and get more information.

Reference

Pujade-Lauraine E, Selle F, Scambia G, et al. Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): phase IIIb OReO/ENGOT Ov-38 trial. Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021; Virtual. Abstract LBA33.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content